Juno Therapeutics Inc (NASDAQ:JUNO) - Share price - Overview

Stock Report

Juno Therapeutics Inc JUNO

Last Price
$29.00

Day Change
2.02|7.49%

As of 23/06/2017
19:58:21 EDT | USD
Minimum 15 Minutes Delay.

Last Close26.98
Day Range26.62 - 29.25
Mkt Cap3.08Bil
52-Wk Range17.52 - 42.98
Yield %-
ISINUS48205A1097
Volume3,713,133
P/E-11.65
P/S33.44
P/CF-16.03

Share Price

Financials
201420152016
More ...
Income Statement
Revenue-18.2279.36
Operating Income-232.76-244.10-255.60
Net Income-243.41-239.38-245.58
Basic EPS-36.82-2.72-2.42
Avg. Diluted Shares Outstanding888101
Balance Sheet
Current Assets439.24951.84772.33
Non Current Assets49.93493.29577.13
Total Assets489.161,445.131,349.46
Current Liabilities100.59119.73114.89
Total Liabilities100.63303.60271.76
Total Equity388.531,141.531,077.70
Cash Flow
Operating Cash Flow-82.557.33-189.81
Capital Expenditure-2.96-28.18-56.25
Free Cash Flow-85.50-20.86-246.06

In millions, except "Basic EPS". Currency is USD.

Company Profile

Juno Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing products that use human cells as therapeutic entities and, although there have been significant advances in cell-based immunotherapy.

Sector

Healthcare

Industry

Biotechnology

Fiscal Year Ends

December

Employees

553
Key Stats
More ...
Price/Earning TTM-10.84
Price/Book2.82
Price/Sales TTM31.13
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % TTM-322.10
Net Margin % TTM-309.47
ROE TTM-22.13
Debt/Equity-
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.